ArticleEmerging infectious diseases2024
Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinically Relevant Risk of Hepatitis B Virus Infection and Reactivation in People With HIV After Withdrawal of Anti-HBV-Active Antiretroviral Therapy in Japan.Open forum infectious diseases · 2026Article
- Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV.AIDS (London, England) · 2026Review
- Hepatitis B virus outcomes in people with HIV after cessation of tenofovir-containing antiretroviral therapy: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort.Infectious diseases and therapy · 2026Article
- Post-marketing safety signals, therapeutic failure, and product-use issues reported with injectable Cabenuva: A FAERS disproportionality analysis.Journal of public health research · 2026Article
- Use of dual ART in individuals with different HBV serological patterns.Current opinion in HIV and AIDS · 2026Review
- Liver disease in people living with HIV infection: a changing landscape.Nature reviews. Gastroenterology & hepatology · 2026Review
- Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics.HIV medicine · 2025Observational
- A Quality Improvement Pilot to Increase Hepatitis B Screening and Optimize Patient Selection for the Switch to Two-Drug Antiretroviral Regimens in People With HIV.Open forum infectious diseases · 2025Article
- Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: What are the risks? What are the clinical implications?HIV medicine · 2025Article
- To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?Open forum infectious diseases · 2025Article
- Serology change-based clinical interpretation of indeterminate serostatus post-hepatitis B virus infection in people living with HIV.PloS one · 2025Article
- Acute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine.ACG case reports journal · 2025Article
- Feasibility and Implementation Considerations for Long-Acting Antiretroviral Therapy in Pakistan: A Qualitative Study of Healthcare Providers and Programmatic Stakeholders.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.